Diagnostic Biomarkers Market Report 2026

Diagnostic Biomarkers Market Overview

• Diagnostic Biomarkers market size has reached to $75.46 billion in 2025 • Expected to grow to $155.92 billion in 2030 at a compound annual growth rate (CAGR) of 15.5% • Growth Driver: Rising Cancer Incidence And Its Impact On Market • Market Trend: Advancing Non-Invasive Diagnostic Biomarkers For Early Disease Detection • North America was the largest region in 2025.

What Is Covered Under Diagnostic Biomarkers Market?

A diagnostic biomarker is a biological measure that assists in the diagnosis of a disease, helping to differentiate it from other conditions. It can encompass various findings, including laboratory results, radiological images, genetic markers, and physiological changes, and may also provide insights into disease progression and treatment efficacy. The main types of products in diagnostic biomarkers are safety biomarkers, efficacy biomarkers, and validation biomarkers. Safety biomarkers are measurable indicators that assess the potential risk of toxicity or adverse effects associated with a medical treatment or environmental exposure and help determine whether a therapy is safe for patients by monitoring biological responses that may indicate harm. The applications include oncology, metabolic disease, and neurological disease for end users such as hospitals, cancer research institutes, and diagnostic labs.

What Is The Diagnostic Biomarkers Market Growth Forecast?

The diagnostic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $155.92 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to advancements in omics technologies, personalized medicine growth, ai-based biomarker discovery, regulatory approvals for novel biomarkers, demand for predictive diagnostics. Major trends in the forecast period include rising adoption of precision diagnostic biomarkers, increasing use of genomic and proteomic biomarkers, expansion of biomarkers in oncology diagnostics, integration of biomarker data with clinical analytics, growing demand for early disease detection.

Global Diagnostic Biomarkers Market Segmentation

1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers 2) By Application: Oncology, Metabolic Disease, Neurological Disease 3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs Subsegments: 1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers 2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers 3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers

What Is The Driver Of The Diagnostic Biomarkers Market?

The growing prevalence of cancer drives the growth of the diagnostic biomarkers market going forward. The growing prevalence of cancer is driven by factors such as aging populations, lifestyle changes, environmental exposures, and improved diagnostic capabilities. Diagnostic biomarkers play a crucial role in cancer by enabling early detection, precise diagnosis, and personalized treatment strategies, improving patient outcomes. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. The increasing prevalence of cancer is driving the growth of the diagnostic biomarkers industry.

Key Players In The Global Diagnostic Biomarkers Market

Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS

Global Diagnostic Biomarkers Market Trends and Insights

Major companies in the diagnostic biomarkers market are focused on developing non-invasive testing methods, such as blood-based biomarker tests, to enhance patient comfort and accessibility with personalized treatment strategies. A blood-based biomarker test refers to a diagnostic tool that analyzes specific biological markers in the blood to detect or monitor diseases, such as Alzheimer's, in a minimally invasive manner. For instance, in July 2023, Quanterix Corporation, a US-based life sciences company, launched LucentAD, a blood-based biomarker test designed to assist healthcare providers in diagnosing Alzheimer's disease (AD) in patients exhibiting early cognitive symptoms. The test measures plasma levels of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker associated with amyloid pathology in the brain, a key indicator of AD. By providing a less invasive and more accessible diagnostic tool compared to traditional methods like cerebrospinal fluid analysis or amyloid positron emission tomography, LucentAD aims to streamline the evaluation process for suspected Alzheimer's patients.

What Are Latest Mergers And Acquisitions In The Diagnostic Biomarkers Market?

In September 2024, Trinity Biotech, an Ireland-based clinical diagnostics company, acquired Metabolomics Diagnostics for approximately $1.3 million. This acquisition provides Trinity Biotech with a strategically valuable mass spectrometry platform integrated with machine learning-driven bioinformatics. Metabolomics Diagnostics is an Ireland-based company specializing in novel biomarker-based diagnostic solutions for complex diseases.

Regional Outlook

North America was the largest region in the diagnostic biomarkers market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diagnostic Biomarkers Market?

The diagnostic biomarkers market consists of revenues earned by entities by providing services such as biomarker assay development and validation, biomarker-based diagnostic testing services, clinical trial support services, and data management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diagnostic biomarkers market also includes sales of biomarker assays, liquid biopsy kits, digital biomarkers, and genetic testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diagnostic Biomarkers Market Report 2026?

The diagnostic biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.